Immuron CEO, Steven Lydeamore to host an investor webinar
February 15 2023 - 6:00AM
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and
globally integrated biopharmaceutical company that has developed
two commercially available oral immunotherapeutic products for the
treatment of gut mediated diseases, invites investors to join a
live webcast hosted by Steven Lydeamore, CEO of Immuron Limited.
Tuesday, 28 February 2023 at 11:00am Australian Eastern Standard
Time (AEDT). To register in advance for this webinar, please follow
this link:
https://us02web.zoom.us/webinar/register/WN_Gum4B9IDS-S6C1eMKr0Zqw
After registering, you will receive a confirmation email containing
information about joining the webinar. |
This release has been authorised by the directors of Immuron
Limited.
COMPANY
CONTACT:
Steven Lydeamore Chief Executive
Officer Ph: +61 (0)3 9824 5254 info@immuron.com
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a novel and safe
technology platform with one commercial asset generating revenue.
In Australia, Travelan® is a listed medicine on the Australian
Register of Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travellers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licenced natural health product (NPN 80046016) and
is indicated to reduce the risk of Travellers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection in accordance with section 403 (r)(6) of the Federal
Drug Administration (FDA).
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024